Single cell sequencing aided researchers in identifying a previously undiscovered molecule in the brain.
The assistant professor of systems pharmacology and translational therapeutics, who studied with Carl June as a postdoctoral fellow, combines his two research passions—gene therapy and investigating ‘little known’ biology—in the pursuit of new knowledge.
Pairing their expertise, Nilam Mangalmurti of the Perelman School of Medicine and Christopher Hunter of the School of Veterinary Medicine have been working to understand the protective and harmful aspects of the immune response, including in COVID-19.
The researchers, from the Annenberg Public Policy Center and the Perelman School of Medicine, join a class of honored scholars recognized for their unique and ongoing contributions to original research.
Research led by the School of Veterinary Medicine’s Rumela Chakrabarti identified a molecular pathway responsible for the disease’s progression and spread.
While the world works to flatten the curve, scientists at Penn and Wistar hope to deliver the COVID-19 pandemic’s silver bullet: a vaccine that effectively protects people from infection.
Penn researchers have shown success using genetically engineered macrophages, an immune cell that eats invaders in the body, to target solid tumors.
A Penn study shows a better clinical response to immunotherapy correlates with higher ratio of tumor mutations detected by a liquid biopsy.
In the first U.S. clinical trial, cells removed from patients and brought back into the lab were able to kill cancer months after their original manufacturing and infusion.
A new study identifies the mechanism that prevents cell death, and can guide future immunotherapy strategies in patients whose blood cancers are resistant to CAR T therapy.
Una O’Doherty of the Perelman School of Medicine commented on a study that appeared to fully suppress HIV without using drugs. “It’s certainly encouraging but speculative,” she said. “I need to see more before I would say, ‘Oh, she’s cured.’”
FULL STORY →
Paul Offit of the Perelman School of Medicine said the benefits of a repurposed vaccines are limited. “We are much better off with a vaccine that induces specific immunity,” he said.
FULL STORY →